INSTITUTO-COORDENADAS
13.10.2020 12:46:08 CEST | Business Wire | Press release
Barcelona’s efforts to become a safe destination for tourists have meant that, of all of Europe’s main tourism destinations, the city and its surrounding areas have been ranked as one of most committed to health safety matters. Monitoring and advice, alongside the involvement of the tourism sector’s main actors, have provided Barcelona with international acknowledgment that will benefit the sector’s recovery. Those are the main conclusions of an ongoing study by Institute Coordenadas into the impact of Covid-19 on the tourism industry.
One of the key indicators that place Barcelona at the forefront for safe spaces internationally is the backing for the city from the World Travel and Tourism Council (WTTC), which has launched a global quality stamp for tourist destinations that provided the strongest guarantees that their public spaces are Covid-secure. Barcelona is a member of the elite group of major European cities that safely welcome a high number of tourists. As such, the city is striving to provide the safest conditions for visitors, around 28 million of whom come to the Catalan capital every year, joining its population of just over 1.6 million. Seville was also acknowledged by the WTTC, along with other destinations in Portugal, Saudi Arabia and Cancun, Mexico.
Barcelona’s seventh position (and the title of top-ranked Spanish city) in the Saffron City Brand Barometer 2020 of the cities with the strongest tourism brands is also a key factor. Similarly, the Global Safe Site certification from Bureau Veritas highlights strict compliance with hygiene and safety measures in Barcelona, which was also the first Spanish city to be awarded the distinction. Key tourist infrastructure such as Park Güell, the city’s zoo and the Tibidabo amusement park have all been awarded the Safe Tourism Certified distinction by the Institute for Spanish Tourism Quality (ICTE), which marks the implementation of a specific Covid-19 risk prevention system. Furthermore, Barcelona has been Biosphere-certified since 2011 as an urban destination committed to sustainability.
The website promoted by Barcelona City Council as part of the Barcelona Safe City/Safe Visit initiative is a key element in the process of getting the city moving again post-Covid. The portal can be used by companies and professionals to check the information related to their respective fields and for obtaining a personalised report featuring all the necessary elements to ensure protocols adapt to maximum safety requirements.
The involvement of actors from different municipal levels has been one of the factors that has allowed Barcelona to compete to become a safer city in terms of health. The Safe City initiative included an interdisciplinary working group with members from the Catalan Directorate of Tourism, the Public Health Agency of Catalonia, the Municipal Civil Defence Service, the Guàrdia Urbana municipal police force, BCNecologia/Barcelona Urban Ecology Agency, the city’s Department of Commerce, its Culture Institute and the Barcelona Sports Institute, municipal company B:SM, trade fair organisation Fira de Barcelona, the Turisme de Barcelona Consortium and ISGlobal.
Another aspect that will improve safety features for tourists in Barcelona is the introduction of the app currently being put together by the Turisme de Barcelona Consortium and Barcelona City Council. The app will allow users to check on health recommendations and the situation at visitor locations, so as to avoid crowds and queueing. The app’s initial launch phase will feature opening times and entry points for the most popular tourist destinations, along with guidance for health and mobility. Plans for the second phase include real-time information and the option of booking ahead to ensure safer management of tourist activities. The app is being developed by Eurecat Technology Centre in collaboration with the Mobile World Capital Barcelona Foundation and Barcelona Tech City.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
